Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03388398
Other study ID # 1R01HD080492-01
Secondary ID 1R01HD080492-01
Status Completed
Phase
First received
Last updated
Start date January 2012
Est. completion date January 2019

Study information

Verified date May 2023
Source University of California, Berkeley
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates the impact of Zimbabwe's program for the prevention of mother-to-child HIV transmission (PMTCT) on vertical transmission of HIV infection and HIV-free survival among infants exposed to HIV. The study will test the hypothesis that the accelerated PMTCT program in Zimbabwe will result in fewer new HIV infections in infants and will increase infant survival.


Description:

The World Health Organization (WHO) recommends that all pregnant women receive antiretroviral therapy (ART) during pregnancy and breastfeeding ("Option B") or ideally throughout their lives regardless of clinical stage ("Option B+"). In February 2013, Zimbabwe's Ministry of Health and Child Welfare (MoHCW) declared that Zimbabwe would begin implementing Option B+ in October of 2013. This impact evaluation utilizes serial population-based, community-level surveys to comprehensively assess the prevention of mother-to-child HIV transmission strategy (PMTCT) 'Option B+' among mother-infant pairs in Zimbabwe. The investigators will assess the population-level impact of Option B+ in Zimbabwe using serial community-based cross-sectional serosurveys with data from three time points: 2012 (pre-Option A standard of care), 2014 (post-Option A / pre-Option B+), and 2017 (post Option B+ implementation) in order to monitor population-level trends in MTCT and HIV-free infant survival. The investigators will compare outcomes among infants from 2017 to outcomes among mother-infant pairs who participated in similar surveys conducted in 2012 and 2014. These community-level data, along with in-depth facility survey data, will also allow the investigators to examine impact heterogeneity by the extent of integration of PMTCT and ART services at the facility. Together with effectiveness data from the serosurveys, facility-level resource utilization and cost data will allow assessment of Option B+ cost-effectiveness. In addition, this study will also include a population-based, community-level survey conducted in 2017 to assess retention of mothers in ART services after weaning (19-36 months postpartum). These data will allow the investigators to assess HIV-infected mothers' retention in care at the time of the survey, when most mothers will have stopped breastfeeding


Recruitment information / eligibility

Status Completed
Enrollment 30642
Est. completion date January 2019
Est. primary completion date July 2018
Accepts healthy volunteers
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria Mothers-Infant pairs: - Mother or caregiver is 16 years of age or older - Delivered or provides care for an infant (alive or deceased) who is or who would have been 9-18 months of age at the time of the survey - Able and willing to provide written informed consent Exclusion Criteria Mothers-Infant pairs: - Mother or caregiver is younger than 16 years of age - Infant (alive or deceased) is not/would not have been 9-18 months of age at the time of the survey Inclusion Criteria Mothers/Caregivers: - At least 16 years of age or older - Delivered an infant (alive or deceased) who is or who would have been 19-36 months of age at the time of the survey - Able and willing to provide written informed consent Exclusion Criteria Mothers/Caregivers: - Mother or caregiver is younger than 16 years of age - Infant (alive or deceased) is not/would not have been 19-36 months of age at the time of the survey Inclusion Criteria Healthcare Staff: - At least 18 years of age or older - Currently providing PMTCT services at one of the 157 selected facilities - Able and willing to provide written informed consent Exclusion Criteria Healthcare Staff: - Health care staff is younger than 18 years of age - Health care staff is not currently providing PMTCT services at one of the 157 selected facilities Inclusion Criteria Providers: - At least 18 years of age or older - Currently providing ANC or ART care directly to clients at one of the 20 purposefully selected facilities - Splitting time as a provider between one or more of the following HIV services: HIV testing and counseling (HTC), prevention of mother-to-child transmission (PMTCT), and male circumcision (MC) - Able and willing to provide written informed consent Exclusion Criteria Providers: - Provider is younger than 18 years of age - Currently not providing ART care directly to clients at one of the 20 purposefully selected facilities - Does not split time as a provider between one or more of the following HIV services: HIV testing and counseling (HTC), prevention of mother-to-child HIV transmission (PMTCT), and male circumcision (MC) Inclusion Criteria Patients: - At least 18 years of age or older - Received HIV testing and counseling (HTC), prevention of mother-to-child HIV transmission (PMTCT), or male circumcision (MC) services at one of the 20 purposefully selected facilities on the day of the interview - Able and willing to provide verbal consent Exclusion Criteria Patients: - Patient is younger than 18 years of age - Did not receive HIV testing and counseling (HTC), prevention of mother-to-child HIV transmission (PMTCT), or male circumcision (MC) services at one of the 20 purposefully selected facilities on day of interview

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (8)

Lead Sponsor Collaborator
University of California, Berkeley Centre for Sexual Health and HIV/AIDS Research Zimbabwe (CeSHHAR Zimbabwe), Children's Investment Fund Foundation, Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT)., Elizabeth Glaser Pediatric AIDS Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Liverpool School of Tropical Medicine, Ministry of Health and Child Welfare, Zimbabwe

Outcome

Type Measure Description Time frame Safety issue
Primary Vertical transmission of HIV infection Proportion of infants born to HIV-infected mothers who were HIV-infected 9-18 months after birth
Primary HIV-free survival among infants exposed to HIV Proportion of infants born to HIV-infected mothers who were alive and HIV-uninfected 9-18 months after birth
Secondary Retention of mothers in antiretroviral therapy services (ART) services after weaning The proportion of HIV-infected mothers who were initiated on ART and who continued ART after weaning 19-36 months postpartum
Secondary Time between weaning and discontinuation of antiretroviral therapy services (ART) among mothers who did not continue ART after weaning Average time between delivery and discontinuation of ART among those mothers who did not continue ART 19-36 months postpartum
Secondary Heterogeneity of the impact of Option B+ on HIV-free survival among infants 9-18 months of age by the extent of integration of PMTCT and anti-retroviral therapy (ART) services at health facilities HIV-free survival in health facility catchment areas stratified by the extent of integration of PMTCT and ART services at the health facility Baseline
Secondary Heterogeneity of the impact of Option B+ on mother-to-child transmission of HIV (MTCT) among infants 9-18 months of age by the extent of integration of PMTCT and anti-retroviral therapy (ART) services at health facilities MTCT in health facility catchment areas stratified by the extent of integration of PMTCT and ART services at the health facility Baseline
Secondary Cost-effectiveness of Option B+ compared to the standard of care before Option A Facility costing data and HIV-free survival and MTCT in health facility catchment areas in 2012 compared to 2017 Baseline
Secondary Cost-effectiveness of Option B+ compared to Option A Facility costing data and HIV-free survival and MTCT in health facility catchment areas in 2012 compared to 2014 Baseline
Secondary Variability in health facility accesibility Accessibility of health facilities assessed using exit interviews with patients receiving care at health facilities Baseline
Secondary Variability in health facility quality of available services Quality of available services at health facilities assessed using exit interviews with patients receiving care at health facilities, and clinical vignettes and time and motion studies with healthcare providers at health facilities Baseline
Secondary Variability in health facility appropriateness of available services Appropriateness of available HIV testing and counseling (HTC), prevention of mother-to-child transmission of HIV (PMTCT) and male circumcision (MC) services assessed using clinical vignettes with healthcare providers at health facilities Baseline
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Recruiting NCT06033547 - A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants Phase 1
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT06072443 - AURORA Study-A Transformative Approach to Support PrEP Medication Persistence
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1